McKesson Appoints New Chief Accounting Officer
Ticker: MCK · Form: 8-K · Filed: Jun 3, 2024 · CIK: 927653
Sentiment: neutral
Topics: executive-appointment, compensation, cao
Related Tickers: MCK
TL;DR
McKesson names Michelle Duca as new CAO, effective June 3rd. Big pharma supply chain exec shuffle.
AI Summary
McKesson Corporation announced on May 28, 2024, the appointment of Michelle L. Duca as Senior Vice President and Chief Accounting Officer, effective June 3, 2024. Duca will receive an annual base salary of $450,000 and will be eligible for the company's annual incentive plan and long-term equity awards. She previously served as Vice President, Corporate Controller at McKesson.
Why It Matters
This appointment signifies a key leadership change in financial oversight for McKesson, potentially impacting financial reporting and investor confidence.
Risk Assessment
Risk Level: low — The filing details a routine executive appointment and compensation, which typically carries low risk.
Key Numbers
- $450,000 — Annual Base Salary (For the new Chief Accounting Officer, Michelle L. Duca.)
Key Players & Entities
- McKesson Corporation (company) — Filer
- Michelle L. Duca (person) — Appointed Senior Vice President and Chief Accounting Officer
- June 3, 2024 (date) — Effective date of appointment
- $450,000 (dollar_amount) — Annual base salary for Michelle L. Duca
FAQ
Who has been appointed as the new Senior Vice President and Chief Accounting Officer of McKesson Corporation?
Michelle L. Duca has been appointed as the new Senior Vice President and Chief Accounting Officer of McKesson Corporation.
When is Michelle L. Duca's appointment effective?
Michelle L. Duca's appointment is effective June 3, 2024.
What is Michelle L. Duca's annual base salary?
Michelle L. Duca's annual base salary is $450,000.
What was Michelle L. Duca's previous role at McKesson?
Michelle L. Duca previously served as Vice President, Corporate Controller at McKesson.
What other compensation is Michelle L. Duca eligible for?
Michelle L. Duca is eligible for McKesson's annual incentive plan and long-term equity awards.
Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-06-03 08:08:02
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value MCK New York Stock Exchange
Filing Documents
- mck-20240528.htm (8-K) — 35KB
- ex991-502boardofdirectorap.htm (EX-99.1) — 9KB
- mck-20240528_g1.jpg (GRAPHIC) — 11KB
- mckessonlogoa03.jpg (GRAPHIC) — 11KB
- 0000927653-24-000044.txt ( ) — 270KB
- mck-20240528.xsd (EX-101.SCH) — 3KB
- mck-20240528_def.xml (EX-101.DEF) — 16KB
- mck-20240528_lab.xml (EX-101.LAB) — 30KB
- mck-20240528_pre.xml (EX-101.PRE) — 17KB
- mck-20240528_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors; Election of Director On May 31, 2024, the Board of Directors ("Board") of McKesson Corporation ("Corporation") elected Deborah Dunsire, M.D. as a director of the Corporation and appointed her to the Board's Compensation and Talent Committee and Finance Committee, effective June 3, 2024. Dr. Dunsire joins the Board with over 30 years of experience leading organizations in the biopharmaceutical, oncology and other specialty industries. Most recently, from 2018 to 2023, she served as president and chief executive officer of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases. Prior to that, she held executive leadership roles for several pharmaceutical companies including XTuit Pharmaceuticals, FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa and received her medical degree from the University of Witwatersrand in Johannesburg, South Africa. In connection with her service as a non-employee director, Dr. Dunsire will be indemnified and compensated in accordance with the Corporation's standard indemnification and compensation policies and practices for non-employee directors of the Board as described in the Corporation's Proxy Statement for its 2023 Annual Meeting of Shareholders filed with the Securities and Exchange Commission on June 9, 2023. Linda Mantia and Susan R. Salka will not be standing for re-election at the Corporation's 2024 annual meeting of shareholders ("Annual Meeting"), and their terms will expire effective at the Annual Meeting.
01
Item 7.01 Regulation FD Disclosure. On June 3, 2024, the Corporation issued and posted on its website (https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/ and https://investor.mckesson.com/news/default.aspx) a news release announcing the election of Dr. Dunsire to the Board and that Mses. Mantia and Salka will not be standing for re-election at the Annual Meeting. A copy of that news release is attached hereto as Exhibit 99.1. The information contained in this item, including Exhibit 99.1, is furnished to the Commission, but shall not be deemed "filed" with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, except as expressly stated in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 News release issued by McKesson Corporation on June 3, 2024 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 3, 2024 McKesson Corporation By: /s/ Michele Lau Michele Lau Executive Vice President and Chief Legal Officer